

UNCLASSIFIED

AD NUMBER
ADB274521
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 2001. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 28 July 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-00-1-0606

TITLE: Role of Sister Chromatid Cohesion in the Apoptotic
Response of Normal and Malignant Mammary Cells with
Known Aneuploidy

PRINCIPAL INVESTIGATOR: Debananda Pati, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030

REPORT DATE: September 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Sep 01). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020124 306

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM. -

LIMITED RIGHTS LEGEND

Award Number: DAMD17-00-1-0606
Organization: Baylor College of Medicine

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Mon 12/28/01

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2001		3. REPORT TYPE AND DATES COVERED Final (1 Sep 00 - 31 Aug 01)
4. TITLE AND SUBTITLE Role of Sister Chromatid Cohesion in the Apoptotic Response of Normal and Malignant Mammary Cells with Known Aneuploidy			5. FUNDING NUMBERS DAMD17-00-1-0606	
6. AUTHOR(S) Debananda Pati, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030 E-Mail: pati@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Sep 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Chromosomal segregation abnormalities are a common feature of breast cancer and several studies estimate that approximately 70% of breast cancers demonstrate aneuploidy. Overall, aneuploid tumors have a worse prognosis compared with diploid tumors. Our laboratory has recently isolated the human homolog of the Rad21 cohesin protein (hRad21) as a protein that interacts with the human Cdc34 ubiquitin-conjugating enzyme. The cohesin proteins are required for proper chromosomal segregation in many eukaryotic organisms. Our work led to the unexpected finding that hRad21 undergoes specific cleavage early in apoptosis. Based on this work, we proposed the novel hypothesis that in mammalian cells chromosomal segregation and the apoptotic cell death pathway are directly linked. In this CONCEPT award we have attempted to test this hypothesis. From these studies, it is apparent that cohesin Rad21 may act as an interface between cohesion and cell death, and its cleavage may signal subsequent events of apoptosis, including DNA degradation. It is likely that hRad21 helps maintain chromosomal stability in mammary cells, and its dysregulation results in aberrant cohesion that leads to aneuploidy. This knowledge will be helpful in the derivation of new strategies for the prevention and treatment of breast cancer.				
14. SUBJECT TERMS Cell Biology, Pathobiology, Cell Cycle				15. NUMBER OF PAGES 12
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

	Page#
Cover.....	
SF298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	9
References.....	10

INTRODUCTION

Normal development and homeostasis require the orderly regulation of both cell proliferation and cell survival. Cell death by apoptosis plays an essential role in normal development and physiology in the breast⁸ as well as in the development of breast cancer^{16,18}. The degree of apoptosis can be an important factor in both the progression of breast cancer and the response to treatment^{5,10}. A high apoptotic index (number of apoptotic cells per square millimeter of neoplastic tissue) is related to malignant cellular features and is an indicator of invasiveness and cell proliferation in breast cancer¹⁰. Treatment of breast cancer is improved by increasing the percentage of cells undergoing apoptosis. Thus, cell cycle progression and control of apoptosis are thought to be intimately linked processes. Activation of the cell cycle plays a significant role in the regulation of apoptosis⁷; in some cell types and under certain conditions, apoptosis has been shown to occur only at specific stages of the cell cycle⁹. Although proteins that regulate apoptosis have been implicated in restraining cell cycle entry⁶ and controlling ploidy¹², the effector molecules at the interface between cell proliferation and cell survival have remained elusive. **Our aim in this project was to identify the effector molecules that act as a link between cell proliferation, cell survival and chromosome stability. A novel concept initiated in this project is the idea that chromosomal segregation and apoptotic pathways are interlinked and have a role in the development of aneuploidy in breast tumors. The nuclear signal responsible for marking cells destined for programmed death remains a mystery. Some of the untested hypotheses that we set out to explore in this project include whether the nuclear apoptotic signal is linked to sister chromatid cohesion and sister separation during the terminal stages of mitosis, and alternatively, whether proteins involved in apoptosis control cohesion and chromosomal segregation.**

BODY

During the postdoctoral research fellowship funded by the US Army Breast Cancer Research Program (DAMD 17-96-1-6087), the PI isolated the cDNA encoding human Rad21 (Scc1/Mcd1 in budding yeast) in a two-hybrid screen as an interactor of human Cdc34 ubiquitin-conjugating enzyme^{14,15}. Analyses of Rad21 function in fission yeast, *S. pombe*, and Scc1/Mcd1 in budding yeast, *S. cerevisiae*, have demonstrated that the nuclear phosphoprotein is required for appropriate chromosomal segregation during the normal mitotic cell cycle and double-strand break repair after DNA damage^{3,13}. In budding yeast, loss of cohesion at the metaphase-anaphase transition is accompanied by proteolytic cleavage of the Scc1/Mcd1 protein^{17,13}, followed by its dissociation from the chromatids^{11,13}. Cleavage depends on Esp1 protein (called separin/separase), which is complexed with its inhibitor, Pds1 (also known as securin), before anaphase⁴. In summary, the **Scc1/Mcd1/Rad21 plays a critical role in the eukaryotic cell division cycle by regulating sister chromatid cohesion and separation at the metaphase to anaphase transition.** In mammals, however, little is known about the role of Rad21 cleavage during sister chromatid separation or its impact in human malignancies.

Aim 1) Evaluation of the role of Rad21 in apoptotic response: Initial studies during this project indicated that hRad21 is differentially expressed in a number of breast cancer

derived cell lines in comparison to normal breast epithelial cells. In these studies we examined the expression pattern of Rad21 in breast cancer cell lines MCF7, MDA-MB-157, MDA-MB-231, MDA-MB-436, BT-20, HBL100, and SKBR-3 (Fig. 1). In these cells, Rad21 appeared to have altered expression patterns. Compared to normal human mammary epithelial cells (H-MEC), Rad21 mRNA is overexpressed in MDA-MB-231 and SKBR-3. Rad21 protein, however, is found to be overexpressed in all the cells tested, except for BT20, where its expression was found to be considerably downregulated. During these studies we have also generated a number of reagents to study the interaction between hCdc34 and hRad21 and the function of hRad21 in human cell cycle and breast cancer. Several constructs of hRAD21 in myc, flag and HA epitope vectors have been constructed. Rabbit polyclonal antisera using the C-terminal 14 amino acids of




Fig. 1: Expression of hRad21 mRNA and protein in human breast lines. GADPH and Actin are shown as loading control




Fig.2A: Cleavage of hRad21 and its translocation to cytoplasm after induction of apoptosis in Molt4 T-cells.

B. Immuno-Precipitation and Western blot analysis of cleaved Rad21 protein in Molt4 cells treated with 15 μ M etoposide for 3h.


C. Inhibition of hRad21 cleavage by caspase inhibitor Z-VADFMK.

hRad21 and a mouse monoclonal antibody to the middle portion of the hRad21 molecule have been raised. Both these antibodies specifically recognize a 120 kDa Rad21 protein in Western blot analyses (Fig.2).

Affinity-purified hRad21 polyclonal antibody can efficiently immunoprecipitate the endogenous hRad21 protein (Fig. 2B) from various human and rodent cell lines. Both of the antibodies have also been tested successfully for immunofluorescent detection of endogenous Rad21 protein in the cell.

In a set of studies to analyze the role of Rad21 in mammalian cells after DNA damage, we have recently identified a novel regulatory mechanism of hRad21 in apoptosis. Induction of apoptosis in multiple human cell lines results in the early (3 hours post insult) generation of 64 kDa and

60 kDa cleavage of hRad2 products. Although hRad21 is a nuclear protein, the cleaved product is found in both nuclear and cytoplasmic fractions after the induction of apoptosis (Fig 2A). The identity of this product is confirmed through its recognition by affinity-purified polyclonal and monoclonal antibodies to hRad21 (Fig. 2B) in cell fractionation experiments and immunofluorescent staining assays (data not shown). This product is detected after the induction of apoptosis by DNA-damaging agents (ionizing radiation and topoisomerase inhibitors) as well as non-DNA-damaging agents (cycloheximide treatment and cytokine withdrawal; data not shown). In addition, equivalent doses of ionizing radiation in cells which are resistant to apoptosis do not generate this band; thus, it is not a simple byproduct of the DNA damage. Interestingly, caspase inhibitors block the apoptosis-mediated cleavage of hRad21 suggesting the involvement of caspases in Rad21 cleavage (Fig. 2C).



Additional data arguing for an important regulatory role of Rad21 in apoptosis include: 1) overexpression of hRad21 causes apoptosis in human cell lines (fig. 3); 2) Cleaved Rad21 translocates from nucleus to cytoplasm early (~2h) after the induction of apoptosis; 3) A number of genes involved in the apoptosis pathway, including death-associated protein kinase and cytochrome C oxidase, interact with hRad21 in a two-hybrid assay.

Fig. 3. Over-expression of Rad21 tagged from a myc epitope, CMV promoter driven vector (pCS2MT), leads to apoptosis-like phenotypes and enhanced caspase 3 activity in cultured human cells.

Aim 2) Expression of Rad21 Protein and mRNA in breast tumor samples:

Expression and localization of the hRad21 protein in normal and malignant breast cancer cells are presently being performed using immunocytochemistry and immunofluorescence techniques. hRad21 efficiently localizes to the nucleus of various mammalian cells assayed by immunofluorescence staining using either the affinity purified polyclonal or monoclonal hRad21 antibodies. Currently, about 250 breast tumor specimens with known status for aneuploidy, estrogen receptor, and a number of other markers with appropriate controls available from the Allred lab at Baylor Breast Center are being used to study the expression and localization of Rad21 protein in these cells using immunohistochemistry^{1,2}/immunofluorescence techniques already established in our lab. The Allred lab has assisted us in developing a robust assay to immunolocalize the hRad21 protein using the monoclonal hRad21 antibody (Fig. 4). Since most referral specimens are fixed in 10% neutral buffered formalin and processed at variable rates and

times, increased sensitivity and standardization of the assay is achieved through the use of heat induced antigen retrieval




Fig. 4: Development of an immunohistochemical assay for the detection of hRad21 in human tissue sections using a monoclonal hRad21 antibody, Note the nuclear signal of Rad21 antigen

post-deparaffinization. Endogenous non-specific protein blocking then follows. Subsequently, incubation with the primary antibody (monoclonal hRad21) is performed, followed by a biotinylated secondary antibody incubation directed against the mouse. These are then followed by incubation in horseradish peroxidase (HRP)-labeled streptavidin, which then binds to the biotin label of the secondary antibody. The entire reaction is then visualized by a incubation with 3,3 diaminobenzidine which, in the presence of HRP, produces a brown reaction product at the site of the antigen-antibody interaction. Enhancement of the reaction product is achieved by the addition of the heavy metal osmium tetroxide, which increases the tone of the reaction product and elevates the signal : noise ratio of the assay. Scoring of immunostained slides for hRad21 expression will be performed according to the protocol recently described for Bcl-2 expression in breast tumor specimens² and based on the proportion of cells staining positive.

Due to difficulty in isolating RNA from frozen tumor specimens, expression of *hRAD21* mRNA will be investigated in a subset of breast tumors with Northern blot analysis. The more sensitive RNase protection assay will be correlated with hRad21 protein levels. Quantitation of *hRAD21* message will be performed using a ³²P-labeled probe detected on a Molecular Dynamics STORM imager. Choice of a normal control for expression studies is more difficult. We will use both the MCF-10F cell line and normal human mammary epithelial cells (H-MEC) as controls. In parallel, the expression of hRad21 will be analyzed in the same set of breast tumor specimens using the monoclonal hRad21 antibody previously described. Quantitation will be performed on a Molecular Dynamics STORM imager using the ECL Plus detection system (Amersham). Normalization for loading will be performed by comparing the expression of house-keeping genes such as actin (for protein) and GADPH (for RNA).

Studies in Progress: Currently we have also focused our efforts on mapping the apoptosis-induced Rad21 cleavage sites through protein sequencing. A preliminary set of studies indicated that the expression of the Rad21 protein in specific cellular compartments leads to the induction of apoptosis. Current experiments explore this further by forcing the expression of the full-length as well as the cleaved Rad21 protein into the cytoplasmic compartment using HIV-TAT expression system. The role of Rad21 in apoptosis has been strengthened further by our recent identification of a number of genes in the apoptosis pathway as potential interactors of hRad21 in a two-hybrid assay.

In summary, apart from the previously described functions of Rad21 in chromosome segregation and DNA repair, cleavage of the protein appears to be an early event in the apoptotic pathway. These results provide the framework for identifying importance of Rad21 functions in the apoptotic response of normal and malignant mammary cells with known levels of aneuploidy.

Key Research Accomplishments

- hRad21 is differentially expressed in a number of breast cancer derived cell lines in comparison to normal breast epithelial cells.
- Over-expression of Rad21 in mammalian cells results in the induction of apoptosis.
- Induction of apoptosis by both DNA-damaging and non DNA-damaging agents results in the cleavage of hRad21 protein and cleaved Rad21 protein localized to the cytoplasm. Caspase inhibitors block the apoptosis-induced cleavage of Rad21 protein.
- In a yeast two-hybrid assay a number of genes involved in the apoptosis pathway, including death-associated protein kinase and cytochrome C oxidase, interact with hRad21.

Reportable Outcomes

Abstract:

Pati, D., and Plon, S.E., Cleavage of human Rad21 cohesin protein: potential role in early apoptosis. Abstract book of the Cell Cycle meeting, Cold Spring Harbor Laboratory, New York, May17-21, 2000, p140 (2000)

Fundings received based on work supported by this Award:

US Army IDEA award (DAMD 01-1-0142)

US Army CDA Award (DAMD 01-1-0143)

Employment:

In part, based on the experience supported by this award, PI was promoted to a Tenure Track assistant professor in the Department of Pediatric Hematology/Oncology at Baylor College of Medicine, Houston, TX starting July 2001.

Conclusions

These results have provided the framework for establishing a link between sister chromatid cohesion, the apoptotic response, and the development of aneuploidy, all of which have not previously been tested in any model system. It is apparent that cohesin Rad21 may act as an interface between cohesion and cell death, and its cleavage may signal subsequent events of apoptosis, including DNA degradation. Our on-going experiments, as a part of the IDEA and CDA awards given for the purpose of elucidating the function of cohesin hRad21 in normal and malignant mammary cells, is expected to shed light on the link between cohesion and apoptosis and their importance in the development of aneuploidy and malignancies. It is likely that hRad21 helps maintain chromosomal stability in mammary cells, and its dysregulation results in aberrant cohesion that leads to aneuploidy. This knowledge will be helpful in the derivation of new strategies for the prevention and treatment of breast cancer.

REFERENCES

1. Allred, D.C., Clark, G.M., Randon, A.K., McGuire, W.L., Immunohistochemistry on histological sections from small (50mg) samples of pulverized breast cancer. *Histotech*, **16**: 117-120 (1993).
2. Berardo, M.D., Elledge, R.M., Moor, C.D., Clark, G.M., Osborn, C.K., Allred, D.C., bcl-2 and apoptosis in lymphnode positive breast carcinoma. *Cancer*, **82**: 1296-1302 (1998).
3. Biggins, S., Murray, A.W., Sister chromatid cohesion in mitosis. *Current Opinion in Genetics and Development*, **9**, 230-236 (1999).
4. Ciosk, R., Zachariae, W., Michaelis, C., Shevchenko, A., Mann, M., Nasmyth, K., An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast. *Cell* **93**, 1067-1076 (1998).
5. Furth, P.A. Apoptosis and the development of breast cancer. In "Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics" (Eds. A. M. Bowcock and N.J. Totowa), Humana Press, NY, p171-180 (1999).
6. Huang, D.C.S., O'Reilly, L.A., Strasser, A., Cory, S. The anti-apoptosis function of bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. *EMBO J.*, **16**: 4628-4638 (1997).
7. Hunter, T., Oncoprotein network. *Cell*, **88**:333-346 (1997).
8. Jacobson, M.D., Weil, M., Raff, M.C. Programmed cell death in animal development. *Cell*, **88**, 347-354 (1997).
9. Levine, A.J., p53, the cellular gatekeeper for growth and division. *Cell*, **88**: 323-331 (1997).
10. Lipponen, P., Apoptosis in breast cancer: relationship with other pathological parameters. *Endocrine Related Cancer* **6**: 13-16 (1999).
11. Michaelis, C., Ciosk, R., Nasmyth, K., Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids. *Cell*, **91**, 35-45 (1997).
12. Minn, A. J., Boise, L.H., Thompson, C.B. Expression of Bcl-X_L and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. *Genes Dev.*, **10**: 2621-2631 (1996).

13. Nasmyth, K., Peters, J.M., Uhlmann, F., Splitting the Chromosome: Cutting the Ties That Bind Sister Chromatids. *Science*, **288**: 1379-1385 (2000).
14. Pati, D., Meistrich, M. L., Plon, S. E., Human Cdc34 and Rad6B ubiquitin-conjugating enzyme target repressors of cyclic AMP-induced transcription for proteolysis. *Mol. Cell. Biol.*, **19**, 5001-5013 (1999).
15. Pati, D., and Plon, S.E., Cleavage of human Rad21 cohesin protein: potential role in early apoptosis. Abstract book of the Cell Cycle meeting, Cold Spring Harbor Laboratory, New York, May17-21, 2000, p140 (2000)
16. Schedin, P.J., Thackray, L.B., Malone, P., Fontaine, S.C., Friis, R.R., Strange, R., Programmed cell death and mammary neoplasia. *Cancer. Treat. Res.*, **83**:3-22 (1996).
17. Uhlmann, F., Lottspeich, F., Nasmyth, K., Sister chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1, *Nature*, **400**, 37-42 (1999).
18. Wu, J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer. *Anticancer Research*, **16**: 2233-9 (1996).



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

28 July 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB233865	ADB264750
ADB265530	ADB282776
ADB244706	ADB286264
ADB285843	ADB260563
ADB240902	ADB277918
ADB264038	ADB286365
ADB285885	ADB275327
ADB274458	ADB286736
ADB285735	ADB286137
ADB286597	ADB286146
ADB285707	ADB286100
ADB274521	ADB286266
ADB259955	ADB286308
ADB274793	ADB285832
ADB285914	
ADB260288	
ADB254419	
ADB282347	
ADB286860	
ADB262052	
ADB286348	
ADB264839	
ADB275123	
ADB286590	
ADB264002	
ADB281670	
ADB281622	
ADB263720	
ADB285876	
ADB262660	
ADB282191	
ADB283518	
ADB285797	
ADB269339	
ADB264584	
ADB282777	
ADB286185	
ADB262261	
ADB282896	
ADB286247	
ADB286127	
ADB274629	
ADB284370	
ADB264652	
ADB281790	
ADB286578	